Related Experiment Videos
The Norway study: plasma concentrations, efficacy, and adverse events
The American Journal of Medicine
|November 28, 1986
Summary
This study found no link between higher piroxicam or naproxen plasma concentrations and improved osteoarthritis efficacy or increased adverse events. Age and sex influenced drug levels but not outcomes.
Area of Science:
- Pharmacology
- Rheumatology
- Clinical Trials
Background:
- Osteoarthritis (OA) management often involves nonsteroidal anti-inflammatory drugs (NSAIDs) like piroxicam and naproxen.
- Understanding the relationship between drug concentration and clinical outcomes is crucial for optimizing OA treatment.
- Previous studies have explored NSAID pharmacokinetics and pharmacodynamics in various patient populations.
Purpose of the Study:
- To investigate the correlation between plasma concentrations of piroxicam and naproxen and their efficacy in osteoarthritis patients.
- To examine the relationship between plasma drug levels and the occurrence of all adverse reactions.
- To assess the association between plasma drug concentrations and serious adverse events, including gastrointestinal issues and heart failure.
Main Methods:
- Analysis of data from Norwegian comparative trials comparing piroxicam and naproxen in osteoarthritis.
- Examination of relationships between measured plasma drug concentrations and clinical endpoints.
- Statistical correlation analysis to determine associations between drug levels, efficacy, and adverse events.
Main Results:
- Plasma concentrations of piroxicam and naproxen were positively correlated with patient age and female sex.
- No significant correlation was found between increasing plasma drug concentrations and improved efficacy in osteoarthritis.
- Efficacy, overall side effects, and serious adverse events were not correlated with higher plasma drug levels.
Conclusions:
- In osteoarthritis patients treated with piroxicam or naproxen, higher plasma drug concentrations do not necessarily translate to better efficacy or a higher risk of adverse events.
- Age and sex are factors influencing drug concentrations, but not the clinical effectiveness or safety profile related to drug levels.
- These findings suggest that therapeutic drug monitoring for efficacy and safety based solely on plasma levels may not be warranted in OA patients on these NSAIDs.